Literature DB >> 25976622

Serum miR-181b Is Correlated with Hepatitis B Virus Replication and Disease Progression in Chronic Hepatitis B Patients.

Fujun Yu1, Guangyao Zhou, Guojun Li, Bicheng Chen, Peihong Dong, Jianjian Zheng.   

Abstract

BACKGROUND: Previously, we reported that microRNA-181b (miR-181b) activates hepatic stellate cells partly through the phosphatase and tensin homolog deleted on chromosome 10 (PTEN)/Akt pathway. AIMS: The main objective of this study was to ascertain whether serum miR-181b expression is correlated with that of liver hepatitis B virus (HBV) DNA and disease progression in chronic hepatitis B (CHB) patients.
METHODS: Serum miR-181b and liver HBV DNA levels were quantified in 64 CHB patients with real-time PCR. Liver fibrosis and necroinflammation were graded according to the Ishak scoring system.
RESULTS: Serum miR-181b levels were evaluated in the CHB group, compared with healthy controls. Expression in patients with HBsAg (+) was higher than that in patients with HBsAg (-). Notably, serum miR-181b and liver HBV DNA levels were significantly correlated (P < 0.05). Serum miR-181 levels were higher in patients with serum HBV DNA > 10(3) IU/ml (P = 0.017), histologic activity index (HAI) >8 (P = 0.001) and fibrosis score >4 (P < 0.0001). Liver HBV DNA levels were higher in patients with abnormal alanine aminotransferase (ALT) values (P = 0.004), serum HBV DNA levels > 10(3) IU/ml (P = 0.034) and fibrosis score >4 (P = 0.006). Using multivariate logistic regression analysis, serum miR-181b was identified as an independent predictor of disease progression (OR 4.172, 95 % CI 1.838-9.473, P = 0.009 for HAI >8; OR 5.387, 95 % CI 2.067-14.036, P = 0.001 for fibrosis score >4).
CONCLUSIONS: Serum miR-181b is correlated with liver and serum HBV DNA levels as well as disease progression in CHB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25976622     DOI: 10.1007/s10620-015-3649-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  35 in total

1.  Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210.

Authors:  Guang-ling Zhang; Yi-xuan Li; Shu-qi Zheng; Min Liu; Xin Li; Hua Tang
Journal:  Antiviral Res       Date:  2010-08-20       Impact factor: 5.970

2.  2004 guidelines for surgical treatment of primary hepatocellular carcinoma.

Authors: 
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2005-05

3.  Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma.

Authors:  Cheng Fang; Dan-Xia Zhu; Hua-Jie Dong; Zhi-Jian Zhou; Yin-Hua Wang; Ling Liu; Lei Fan; Kou-Rong Miao; Peng Liu; Wei Xu; Jian-Yong Li
Journal:  Ann Hematol       Date:  2011-10-11       Impact factor: 3.673

4.  Hepatic stellate cell is activated by microRNA-181b via PTEN/Akt pathway.

Authors:  Jianjian Zheng; Cunzao Wu; Ziqiang Xu; Peng Xia; Peihong Dong; Bicheng Chen; Fujun Yu
Journal:  Mol Cell Biochem       Date:  2014-08-23       Impact factor: 3.396

5.  Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy.

Authors:  David E Amacher; Rick Adler; Athula Herath; R Reid Townsend
Journal:  Clin Chem       Date:  2005-08-11       Impact factor: 8.327

6.  Golgi protein 73(GP73), a useful serum marker in liver diseases.

Authors:  Xiangyi Liu; Xiaohua Wan; Zhongwu Li; Changqing Lin; Yutao Zhan; Xinxin Lu
Journal:  Clin Chem Lab Med       Date:  2011-06-10       Impact factor: 3.694

Review 7.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

Review 8.  The current state of serum biomarkers of hepatotoxicity.

Authors:  Josef Ozer; Marcia Ratner; Martin Shaw; Wendy Bailey; Shelli Schomaker
Journal:  Toxicology       Date:  2007-12-05       Impact factor: 4.221

9.  TGF-β and iron differently alter HBV replication in human hepatocytes through TGF-β/BMP signaling and cellular microRNA expression.

Authors:  Sun O Park; Mukesh Kumar; Sanjeev Gupta
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

10.  Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression.

Authors:  Nicola Coppola; Nicoletta Potenza; Mariantonietta Pisaturo; Nicola Mosca; Gilda Tonziello; Giuseppe Signoriello; Vincenzo Messina; Caterina Sagnelli; Aniello Russo; Evangelista Sagnelli
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

View more
  12 in total

1.  Dual microRNA Screens Reveal That the Immune-Responsive miR-181 Promotes Henipavirus Entry and Cell-Cell Fusion.

Authors:  Chwan Hong Foo; Christina L Rootes; Karla Cowley; Glenn A Marsh; Cathryn M Gould; Celine Deffrasnes; Christopher J Cowled; Reuben Klein; Sarah J Riddell; Deborah Middleton; Kaylene J Simpson; Lin-Fa Wang; Andrew G D Bean; Cameron R Stewart
Journal:  PLoS Pathog       Date:  2016-10-26       Impact factor: 6.823

2.  Serum microRNA-30c levels are correlated with disease progression in Xinjiang Uygur patients with chronic hepatitis B.

Authors:  J Zhang; J Ma; H Wang; L Guo; J Li
Journal:  Braz J Med Biol Res       Date:  2017-05-04       Impact factor: 2.590

3.  MicroRNA-520a suppresses HBV replication in HepG2.2.15 cells by inactivating AKT.

Authors:  Wei Sun; Jinqian Zhang; Jinglong Chen
Journal:  J Int Med Res       Date:  2018-09-07       Impact factor: 1.671

4.  CircMTO1 inhibits liver fibrosis via regulation of miR-17-5p and Smad7.

Authors:  Wei Wang; Ruiling Dong; Yong Guo; Jianan He; Chaopeng Shao; Pin Yi; Fujun Yu; Dayong Gu; Jianjian Zheng
Journal:  J Cell Mol Med       Date:  2019-05-31       Impact factor: 5.310

Review 5.  The Regulatory Role of MicroRNA in Hepatitis-B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) Pathogenesis.

Authors:  Kurt Sartorius; Julia Makarova; Benn Sartorius; Ping An; Cheryl Winkler; Anil Chuturgoon; Anna Kramvis
Journal:  Cells       Date:  2019-11-24       Impact factor: 6.600

6.  Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature.

Authors:  Ana Garcia Garcia de Paredes; Nicolo Manicardi; Luis Tellez; Luis Ibañez; Felix Royo; Javier Bermejo; Carolina Blanco; Constantino Fondevila; Val Fernandez Lanza; Laura Garcia-Bermejo; Juan Manuel Falcon-Perez; Rafael Bañares; Jordi Gracia-Sancho; Agustin Albillos
Journal:  Hepatol Commun       Date:  2020-12-02

7.  Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis.

Authors:  Ana Garcia Garcia de Paredes; Càndid Villanueva; Carolina Blanco; Joan Genescà; Nicolo Manicardi; Juan Carlos Garcia-Pagan; Jose Luis Calleja; Carlos Aracil; Rosa M Morillas; Maria Poca; Beatriz Peñas; Salvador Augustin; Juan G Abraldes; Eldimar Alvarado; Félix Royo; Maria Laura Garcia-Bermejo; Juan Manuel Falcon-Perez; Rafael Bañares; Jaime Bosch; Jordi Gracia-Sancho; Agustin Albillos
Journal:  JHEP Rep       Date:  2021-09-27

Review 8.  Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis.

Authors:  Hans-Theo Schon; Matthias Bartneck; Erawan Borkham-Kamphorst; Jacob Nattermann; Twan Lammers; Frank Tacke; Ralf Weiskirchen
Journal:  Front Pharmacol       Date:  2016-02-24       Impact factor: 5.810

9.  miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2.

Authors:  Hui-Ning Liu; Peng Qie; Guang Yang; Yong-Bin Song
Journal:  Arch Med Sci       Date:  2018-02-02       Impact factor: 3.318

Review 10.  Circulating microRNAs as non-invasive biomarkers for hepatitis B virus liver fibrosis.

Authors:  Diana Gabriela Iacob; Adelina Rosca; Simona Maria Ruta
Journal:  World J Gastroenterol       Date:  2020-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.